Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDA022-BB05 in Advanced/Metastatic Solid Tumors
NCT06413615Phase 2Recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of FDA022-BB05 in breast cancer, endometrial cancer (EC), urothelial carcinoma (UC) and 3 more (3 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Objective Response Rate at 24 months and Adverse Events at 24 months. Started May 2024; status: recruiting.
02
Drugs
FDA022-BB05
03
Conditions
breast cancerendometrial cancer (EC)urothelial carcinoma (UC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06413615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413615.